• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	Advanced Biomed Inc. (ADVB)
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date		2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31
Fiscal Period		Q1-FY2026	Q4-FY2025	Q3-FY2025	Q2-FY2025
Total Revenue
QoQ%
YoY%
Cost Of Revenue
Gross Profit
Gross Margin
Operating Expenses		523,914$	1,212,541$	762,739$	525,729$	520,027$	704,613$	745,412$	651,302$
Operating Income
Operating Margin
Interest Income		448$	9,512$	(24$)	15,417$	10$	33,411$	104$	19,966$
Interest Expenses
Income Before Tax		(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
Tax Expenses
Net Income		(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
Profit Margin
TTM
Earnings to Minority
Earnings to Common Shareholders		(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
QoQ%		44.86%	49.30%	(52.43%)	(241.86%)	67.19%	23.37%	(626.71%)
YoY%		(45.68%)	13.32%	(31.02%)	(524.65%)
Earnings Per Share, Basic		(0.02$)	(0.03$)	(0.07$)	(0.05$)	(0.01$)		(0.05$)	(0.01$)
Earnings Per Share, Diluted		(0.02$)	(0.03$)	(0.07$)	(0.05$)	(0.01$)		(0.05$)	(0.01$)
Unlevered FCF Per Share, Basic		(0.03$)	(0.07$)	(0.17$)		0.00$		(0.05$)
Unlevered FCF Per Share, Diluted		(0.03$)	(0.07$)	(0.17$)		0.00$		(0.05$)
Average Shares, Basic		21,640,000	21,623,695	20,479,101	20,000,000	20,000,000		20,000,000	20,000,000
Average Shares, Diluted		21,640,000	21,623,695	20,479,101	20,000,000	20,000,000		20,000,000	20,000,000
EBIT		(386,901$)	(701,611$)	(1,383,874$)	(907,904$)	(265,580$)	(809,386$)	(1,056,231$)	(145,345$)
EBITDA		(338,909$)	(637,209$)	(1,305,735$)	(907,904$)	(163,362$)	(655,475$)	(973,215$)	(145,345$)

Copy Table ✓